2024
AI-driven Patient-Selection For Preoperative Portal Vein Embolization For Patients With Colorectal Cancer Liver Metastases
Kuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho Vasquez J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. AI-driven Patient-Selection For Preoperative Portal Vein Embolization For Patients With Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024 PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.Peer-Reviewed Original ResearchTotal liver volumeMetastatic colorectal cancer patientsPreoperative portal vein embolizationColorectal cancer liver metastasesPortal vein embolizationCancer liver metastasesMulticenter retrospective studyColorectal cancer patientsStudent's t-testBoard-certified radiologistsVein embolizationConsecutive patientsLiver metastasesLiver volumePatient selectionRetrospective studyCancer patientsRadiomic featuresInclusion criteriaPatientsSemi-automatic segmentationLab valuesT-testSDAUCImage-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy?
Chan S, Cornman-Homonoff J, Lucatelli P, Madoff D. Image-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy? Clinical Imaging 2024, 111: 110185. PMID: 38781614, DOI: 10.1016/j.clinimag.2024.110185.Peer-Reviewed Original ResearchLiver venous deprivationPortal vein embolizationRadiation lobectomyVein embolizationResection of HCCMinimally invasive techniquesStandard of careHepatic malignanciesLiver remnantLiver insufficiencySurgical candidacySurgical techniqueHepatocellular carcinomaInvasive techniquesHepatic functionPercutaneous strategiesResectionPatient's likelihoodLobectomyEmbolizationLiverPatientsFLRCarcinomaMalignancyAtezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomes
2023
Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments
Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, Kurup A, Tanzilli A, Tenore L, De Leoni D, Filippiadis D, Giuliante F, Valentini V, Gasbarrini A, Goldberg S, Meijerink M, Manfredi R, Kelekis A, Colosimo C, Madoff D. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers 2023, 15: 308. PMID: 36612304, PMCID: PMC9818393, DOI: 10.3390/cancers15010308.Peer-Reviewed Original ResearchInterventional oncologyLocoregional treatmentCancer patientsNew locoregional treatmentMultiple body systemsLow-risk alternativeImage-guided techniquesLocoregional proceduresSurgical therapyPalliative careInvasive proceduresPotential cureDisease sitesNew indicationsTreatment of diseasesInnovative indicationsOncologyPatientsTreatmentEvidence-reported literatureExpert discussionIndicationsWide spectrumReviewWidespread use
2022
Oncopharmacology in Interventional Radiology
Raja J, Madoff D. Oncopharmacology in Interventional Radiology. Seminars In Interventional Radiology 2022, 39: 411-415. PMID: 36406031, PMCID: PMC9671678, DOI: 10.1055/s-0042-1758076.Peer-Reviewed Original ResearchA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differencesA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic reviewKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 71-90. PMID: 34991070, PMCID: PMC10191161, DOI: 10.6004/jnccn.2022.0001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaStage IV renal cell carcinomaNCCN guidelinesKidney cancerTreatment selectionNCCN Clinical Practice GuidelinesAdvanced renal cell carcinomaSystemic therapy recommendationsFirst-line treatmentPre-existing comorbiditiesClinical practice guidelinesKidney cancer therapyRecommended regimensSystemic therapyRisk stratificationTumor histologyCell carcinomaTreatment recommendationsTherapy recommendationsRisk groupsPractice guidelinesCancer fociTherapy selectionCancer panelPatients
2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal Of The National Comprehensive Cancer Network 2020, 18: 1160-1170. PMID: 32886895, PMCID: PMC10191771, DOI: 10.6004/jnccn.2020.0043.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaKidney cancerStage IV renal cell carcinomaHereditary RCC syndromesNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsNCCN guidelinesRCC syndromesCell carcinomaMultidisciplinary recommendationsTreatment optionsDiagnostic workupTherapy recommendationsGenetic testingPatientsSyndromeCancerRecent updatesGuidelinesCarcinomaWorkupStagingRecommendationsLEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals Of Oncology 2020, 31: s702-s703. DOI: 10.1016/j.annonc.2020.08.1132.Peer-Reviewed Original ResearchP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Ogasawara S, Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ren Z, Modi K, Li J, Siegel A, Dubrovsky L, Kudo M. P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals Of Oncology 2020, 31: s124-s125. DOI: 10.1016/j.annonc.2020.04.189.Peer-Reviewed Original Research
2019
Applications of transcatheter embolotherapy in preparation for liver transplantation and resection
Lin EY, Cornman-Homonoff J, Odisio BC, Madoff DC. Applications of transcatheter embolotherapy in preparation for liver transplantation and resection. Chinese Clinical Oncology 2019, 8: 59. PMID: 31865716, DOI: 10.21037/cco.2019.12.03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLocoregional therapyPost-resection outcomesLiver-directed therapiesAppropriate patient selectionEarly-stage diseasePre-operative periodMaximal potential benefitTranscatheter embolotherapyLiver transplantationPatient selectionSurgical interventionInterventional radiologyPartial hepatectomyTransplantationTherapyPotential benefitsResectionPatientsSurgeryEmbolotherapyHepatectomyDiseaseTranshepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma
Cornman-Homonoff J, Bassik N, Madoff DC. Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma. Clinical Imaging 2019, 59: 188-191. PMID: 31837541, DOI: 10.1016/j.clinimag.2019.09.012.Peer-Reviewed Case Reports and Technical NotesConceptsRecurrent cholangiocarcinomaOnly potential cureRecurrent intrahepatic cholangiocarcinomaPoor patient outcomesUnresectable diseaseGastrointestinal bleedingChemotherapy administrationMyelosuppressive effectsTherapeutic mainstayDismal prognosisIntrahepatic cholangiocarcinomaVariceal embolizationStent placementPortal veinPatient outcomesPotential cureCholangiocarcinomaEmbolizationCytopeniasBleedingRegimenChemotherapyPatientsSurgeryPrognosisManagement of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng SQ, Teng GJ. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019, 4: 721-730. PMID: 31387735, DOI: 10.1016/s2468-1253(19)30178-5.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticEndovascular ProceduresHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsLiver TransplantationNivolumabPatient Care TeamPhenylurea CompoundsPortal VeinPyridinesQuinolinesRadiotherapy, AdjuvantSorafenibStentsVenous ThrombosisConceptsPortal vein tumor thrombosisTumor thrombosisHepatocellular carcinomaOptimise treatment strategiesTranscatheter arterial therapyAdvanced hepatocellular carcinomaManagement of patientsArterial therapySurgical treatmentTreatment strategiesPhysician preferenceNovel treatmentsCarcinomaThrombosisMultidisciplinary teamPatientsReimbursement schemesTreatmentRevascularisationComorbiditiesManagementPrognosisRadiotherapyActive managementTherapyInterventional radiology's role in the diagnosis and management of patients with gallbladder carcinoma.
Fine GC, Smith TA, Stein SI, Madoff DC. Interventional radiology's role in the diagnosis and management of patients with gallbladder carcinoma. Chinese Clinical Oncology 2019, 8: 40. PMID: 31431037, DOI: 10.21037/cco.2019.07.09.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationManagement of patientsGallbladder carcinomaAggressive biliary tract malignancyInterventional radiology’s roleLate disease statesPortal vein embolizationPost-operative complicationsBiliary tract malignancyCommon gastrointestinal malignancyBile leakGastrointestinal malignanciesSurgical candidatesVein embolizationBiliary drainageBiliary obstructionChronic painPorcelain gallbladderPercutaneous imageRisk factorsInterventional radiologistsPatientsCarcinomaTissue samplingDisease statesExtrahepatic Clinical Application of Vessel Tracking Software and 3D Roadmapping Tools: Preliminary Experience
Sundararajan SH, McClure TD, Winokur RS, Kishore SA, Madoff DC. Extrahepatic Clinical Application of Vessel Tracking Software and 3D Roadmapping Tools: Preliminary Experience. Journal Of Vascular And Interventional Radiology 2019, 30: 1021-1026. PMID: 31003843, DOI: 10.1016/j.jvir.2018.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAgedAneurysm, FalseCarcinoma, Renal CellComputed Tomography AngiographyEmbolization, TherapeuticFemaleGastrointestinal HemorrhageHumansImaging, Three-DimensionalKidney NeoplasmsMaleMesenteric Artery, SuperiorPancreaticoduodenectomyPostoperative HemorrhagePredictive Value of TestsPreliminary DataProstateProstatic HyperplasiaRadiographic Image Interpretation, Computer-AssistedRadiography, InterventionalRenal ArteryRetrospective StudiesSoftwareTreatment Outcome
2017
Incorporating Quality of Life Metrics in Interventional Oncology Practice
Li D, Madoff DC. Incorporating Quality of Life Metrics in Interventional Oncology Practice. Seminars In Interventional Radiology 2017, 34: 313-321. PMID: 29249854, PMCID: PMC5730443, DOI: 10.1055/s-0037-1608826.Peer-Reviewed Original ResearchCancer patientsPatients' qualityInterventional radiologistsBrief Pain InventoryVisual analog scaleNumerical rating scaleQuality of lifePalliative intentCancer QualityPain InventoryAnalog scaleLife QuestionnaireOncology practiceLife instrumentsOutcome measuresLife measuresInvasive proceduresFunctional assessmentLife metricsPatientsEuropean OrganizationRating ScaleCancer therapyRadiologistsCommon instrumentsPeriprocedural Bleeding Risk Assessment in Chronic Liver Disease
Fortune B, Madoff D, May B. Periprocedural Bleeding Risk Assessment in Chronic Liver Disease. Digestive Disease Interventions 2017, 01: 306-312. DOI: 10.1055/s-0038-1629916.Peer-Reviewed Original ResearchAdvanced liver diseaseChronic liver diseaseLiver diseaseCLD patientsInternational normalized ratio testsBleeding Risk AssessmentLaboratory abnormalitiesUnnecessary transfusionsBlood productsInvasive proceduresProcedure delaysPatientsDiseaseCoagulopathyPotential harmRiskLaboratory testsBleedingTransfusionRisk assessmentAbnormalitiesClinicians